Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3951276 | 0.87 | MEN1 (0.67) | MEN1KMT2AMAPK10GFERADRA2A | |
| SCHEMBL29544002 | 0.87 | MEN1 (0.67) | MEN1KMT2AMAPK10GFERADRA2A | |
| SCHEMBL1883319 | 0.83 | KMT2A (0.57) | MEN1KMT2AMAPK10GFERADRA2A | |
| SCHEMBL221242 | 0.79 | KMT2A (0.76) | MEN1KMT2AMAPK10GFERADRA2A | |
| SCHEMBL29391624 | 0.79 | KMT2A (0.76) | MEN1KMT2AMAPK10GFERADRA2A | |
| SCHEMBL3948701 | 0.79 | KMT2A (0.57) | MEN1KMT2AMAPK10GFERADRA2A | |
| SCHEMBL31355480 | 0.79 | KMT2A (0.57) | MEN1KMT2AMAPK10GFERADRA2A | |
| SCHEMBL31355479 | 0.79 | KMT2A (0.57) | MEN1KMT2AMAPK10GFERADRA2A | |
| SCHEMBL4243882 | 0.77 | KMT2A (0.73) | MEN1KMT2AMAPK10GFERADRA2A | |
| SCHEMBL11133606 | 0.77 | KMT2A (0.73) | MEN1KMT2AMAPK10GFERADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218360-B1 | TRIAZINE KINASE INHIBITORS | AMGEN INC (US) | 2008-05-28 | — | — | EP | disclosed |
| US-7074789-B2 | Kinase inhibitors | AMGEN INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-6864255-B2 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20040116388-A1 | triazine compoound inhibitors of enzymes that catalyze phosphoryl transfer and/or that bind ATP/GTP nucleotides | AMGEN INC. | 2004-06-17 | — | — | US | disclosed |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. | 2003-05-08 | — | — | US | disclosed |
| EP-1218360-A1 | TRIAZINE KINASE INHIBITORS | Amgen Inc., (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001025220-A1 | TRIAZINE KINASE INHIBITORS | AMGEN INC. (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | FLT4, FLT1, VEGFA | MEN1 3232/4885KMT2A 2665/4885MAPK10 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.